Hammond's Hot Takes Weekly Edition

Research evidence excerpt

Hammond's Hot Takes Weekly Edition

June 7, 2026

●PFE entered into an AI drug discovery license with Chai Discovery. The

collaboration gives PFE access to the AI company’s drug discovery platform for

biologics research.

Developments from a macro / regulatory perspective:

●FDA held a pilot program public hearing for the Commissioner's National

Priority Voucher. The meeting allowed for those interested to share feedback

on the program. Comments largely revolved around the need for more

transparency and clearer communication from the agency and during the CNPV

process, and targeted the program's vulnerability to political interference.

●The FDA granted BIIB's salanersen Breakthough Therapy designation for

spinal muscular atrophy supported by clinically meaningful improvement

observed during its phase 1b study.

●AMGN received EC approval for the use of Imdylltra in extensive-stage small

cell lung cancer in the EU. The approval was supported by the DeLLphi-304

phase 3 study.

●BMY was granted FDA priority review for Camzyos for the treatment

of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The

designation was supported by results from the Phase 3 SCOUT-HCM trial.

●BMY announced an EU label expansion for Opdivo+AVD in frontline

advanced classical Hodgkin lymphoma in patients 12 years or older. Approval

was based on results from the Phase 3 SWOG 1826.

●ABBV announced the EU approval of Aquipta for the acute treatment of

migraine in adults. This adds to its previous EU approval as a daily preventive

treatment for chronic or episodic migraine.

To close out the week, we've rounded up our recently published research:

●Lilly Is The Heavyweight To Get You To Featherweight: Zepbound, Mounjaro

& Foundayo are followed closely behind by next-gen approaches (e.g.,